LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Damora Therapeutics yesterday and set a price target of $45.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sam Slutsky has given his Buy rating due to a combination of factors related to Damora’s differentiated pipeline and development timelines. He highlights DMR-001’s convenient once‑monthly subcutaneous dosing and its robust activity against both type 1 and type 2 CALR mutations, which may offer a clinical and practical edge over Incyte’s IV INCA033989 that has weaker type 2 potency and more burdensome administration.
He also points to the company’s clear regulatory path, with an IND for DMR-001 expected in mid‑2026 and initial proof‑of‑concept data projected to begin in mid‑2027, followed by an expedited move into Phase 3 that leaves Damora only about two years behind the class leader. In addition, Slutsky views the recent acquisition structure and the roughly five years of cash runway as providing solid financial backing to advance DMR-001 and subsequent assets DMR-002 and DMR-003 through key value‑creating milestones.
DMRA’s price has also changed dramatically for the past six months – from $2.870 to $19.200, which is a 568.99% increase.